相信,最近的日本強震海嘯,讓大家重新體認大自然的無情反撲,更讓我們更加珍惜彼此周遭熟悉的人事物,把握現在和當下。
希望大家都能夠繼續不斷的走下去, 永不放棄直到最後, 一起加油!
本網誌設立的目的在於提供MS多發性硬化症的相關醫療資訊,並且以一過來人的身分分享自己發病過程和對抗這個罕見疾病的經驗和心路歷程. 希望我的個人經驗能夠讓同樣遭受這種疾病的人獲得身體上或者是心理上的幫助,而這將是我最大的快樂!! 我更希望這種病不要發生在正常的人身上,希望能夠藉由我的網誌來換醒更多人對於健康的重視!!
按摩緩解便秘的方法
"My fatigue level has improved greatly. I continue to amaze my husband Darren when he gets home from work and I'm still on the go. Unheard of before!!! My sensory or nerve pain has improved greatly. I wonder how I ever lived with it. I feel so much more alert and pulled together. I have been very busy these days. I have been feeling very well since my return home and I have been working very hard on my physiotherapy and am determined to strengthen this leg.
(Dawnia was liberated January 14 - dmcleod@wightman.ca This e-mail address is being protected from spambots. You need JavaScript enabled to view it )
PIERO SCARSELLA (Toronto, Ontario, JAN, 2011)
“I find that my leg strength is a little bit better, I am able to peddle my stationary bicycle longer. My balance is better so that now I can stand up straight, more or less, and keep my balance for a minute or two. My head feels clearer and playing with ideas and numbers is easier. This is good news for me because if all works out as we hope, one day I will go to work and pay taxes, so I will have to become a student again. If everything works out taking courses should be easier for me. Piero can be reached at pieroscarsella@rogers.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it
“My head feels more clear.My blood circulation has improved and my hands, legs, and feet actually warm up now!!!I (Contact Diana at diana@dianazimmer.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it or through her website at www.DianaZimmer.com )
最近國外在靜脈擴張手術一些病友的經驗
天氣影響
默克的多發性硬化症藥物Cladribine未獲美國FDA批準,后者要求前者進行更多分析與研究,以便更好地了解藥物的安全風險。
綜合媒體3月2日報導,德國默克制藥公司(Merck KGaA)周三(3月2日)表示,美國食品和藥物管理局(U.S. Food and Drug Administration,FDA)沒有批準其口服多發性硬化症治療藥Cladribine的上市申請。
上述決定令默克公司遭遇挫折,某個歐盟小組在上個月曾經確認了對於Cladribine的否定意見。
默克制藥在聲明中表示,FDA要求其進行更多分析與研究,以便更好地了解藥物的安全風險以及整體利益風險。默克計劃同FDA舉行一次審查總結會議,以便明確下一步的措施,并且探明現有數據是否能夠解決FDA提出的問題。
在歐盟做出決定之后,默克表示,依然承諾繼續并且完成Cladribine的臨床試驗,但多數分析師已經將此項藥品從其評估中移除。
Cladribine為全球首劑多發性硬化症治療藥品,但僅在澳大利亞與俄羅斯這樣的縫隙市場獲批上市。
作為Cladribine的競爭對手,瑞士制藥商諾華公司(Novartis AG)生產的Gilenya已經在美國與俄羅斯獲批上市,并且上個月獲得了歐洲藥物監管機構的肯定意見。
就先等諾華的Gilenya吧
默克的多發性硬化症藥物Cladribine未獲美國FDA批準
CCSVI和MS一些研究結果
每個人都要珍惜和家人在一起的時刻
打扮得美美的,在舞台上唱唱跳跳,這是我們看到Selina美麗開朗的樣子,但這樣的畫面卻讓Selina忍不住感慨。
Selina在微博上留言,說看到不久前螢幕上活蹦亂跳的自己,才發現不管多樂觀,我失去的再也回不來了,忍不住淚水的潰堤,倒在未婚夫阿中的懷裡,說自己原本是全世界最幸福的女人。
阿中立刻安慰她,「妳現在還是最幸福的人,而且還是個很特別的人」,但Selina哭吼,「只想當個平凡的人,結婚生小孩」,微博上的文字看人讓人鼻酸。
這一幕鼓起勇氣面對大家,背後是多少的心酸跟痛苦。面對鏡頭總是低調不語,阿中默默的在背後支持Selina,只有他才看到Selina無助脆弱的樣子。
阿中還告訴Selina是老天要讓你的生命更有意義,這一席話才讓Selina收起眼淚,繼續展開痛苦的復健行程,最後還說「會努力的當你最幸福最特別的新娘」。
經歷生死劫難,Selina渴望平凡生活,一路走來更見Selina跟阿中堅定不移的愛情,Selina的真實人生,比她在舞台上的演出更讓人感動。
------------------------------------------平凡
Details: The funded investigators, which include an integration of both MS and vascular experts, report progress in establishing their teams, putting their protocols in place, recruiting participants and beginning their studies, as summarized below.
該7個研究團隊前6個月的研究進度如下:
• Dr. Brenda Banwell, The Hospital for Sick Children, Toronto, Ontario: Her team received Research Ethics Board approval in the fall and has begun enrolling participants and studying vein abnormalities in children and teenagers who have MS, and healthy controls of the same age, using non-invasive MRI measures of vein anatomy and novel measures of venous flow, as well as ultrasound. The team’s ultrasound experts have received training in Dr. Zamboni’s original techniques.
Read details of Dr. Banwell’s plans.
• Dr. Fiona Costello, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta: Her team received Research Ethics Board approval in the fall to begin recruiting a cross-section of people with MS compared to other neurological diseases and healthy volunteers. They also recruited two ultrasonography experts who have begun ultrasound scanning as originally used by Dr. Zamboni. Dr. Costello’s team slowed recruitment briefly to upgrade to a new 3T MRI machine (twice as strong as standard clinical MRI) that will be used to perform MR venography scans to compare against the ultrasound tests.
Read details of this team’s plans.
• Dr. Aaron Field, University of Wisconsin School of Medicine and Public Health, Madison: His team will be using MR venography and ultrasound techniques originally used by Dr. Zamboni to investigate CCSVI in people with early and later MS, controls with other conditions and healthy volunteers. A study coordinator is developing a recruitment list and an ultrasound expert has been hired and is slated to receive training in the Zamboni techniques. Dr. Field has been negotiating with the Institutional Review Board on issues related to study details and informed consent, and hopes to have these issues resolved to obtain IRB approval in the coming weeks so that scanning can begin.
Read details of this team’s plans.
• Dr. Robert Fox, Cleveland Clinic, Cleveland: His team has received Institutional Review Board approval for using MR venography, ultrasound, MRI and clinical measures in people with MS or who are at risk for MS (CIS) and comparison groups, and recruitment is ongoing. Two ultrasound researchers underwent training in the technique originally used by Dr. Zamboni, and the team has obtained a new ultrasound machine previously used in other CCSVI studies. The ultrasound team found several aspects of the published methodology ambiguous, and they have standardized the protocol and analysis to achieve consistent results. To share ideas and solutions to these methodological challenges, Dr. Fox’s team has submitted an abstract for consideration for presentation at the American Academy of Neurology’s annual meeting in April.
Read details of this team’s plans.
• Dr. Carlos Torres, The Ottawa Hospital, University of Ottawa, Ontario: His team obtained Research Ethics Board approval in the winter and at once began the first phase of scanning using MR venography in people without MS, which will be used to compare with various scans in people with MS. Dr. Torres’s team has overcome several obstacles including negotiating with the Research Ethics Board over elements of the informed consent form used to explain the study’s procedures and potential outcomes to participants. Team members are slated to be trained using the ultrasound techniques originally used by Dr. Zamboni, and they are on track recruiting more participants for the study.
Read details of this team’s plans.
• Dr. Anthony Traboulsee, UBC Hospital MS Clinic, UBC Faculty of Medicine and Dr. Katherine Knox, Saskatoon MS Clinic, University of Saskatchewan: The teams at both sites have received Research Ethics Board approval and have begun to recruit and scan participants. Their ultrasound technologists were trained by Dr. Zamboni, and they are also using catheter venography and MR venography to investigate the prevalence of CCSVI in people with MS and controls without MS. The radiologists on the teams of Drs. Traboulsee and Knox are meeting in February 2011 to ensure the consistency of their protocols across sites. The teams are on target for accrual of recruits and completion of the study.
Read details of their plans.
• Dr. Jerry Wolinsky, University of Texas Health Science Center at Houston: His team applied in advance and obtained Institutional Review Board approval in the spring, and the team’s neurosonographer has received intensive training for intracranial and extracranial ultrasound scanning techniques. The team has already scanned a significant number of participants, which includes people with different types of MS, people with other conditions, and people with no known health problems. One obstacle Dr. Wolinsky’s team is addressing is the difficulty of recruiting non-MS control subjects who don’t have a personal interest in the purpose of the trial. The team is testing whether other imaging methods can confirm the ultrasound findings, while identifying the most reliable technique to screen for CCSVI.
Read details of this team’s plans.
Going Forward: These seven teams were chosen by an international panel of experts that included specialists drawn from all key relevant disciplines including radiology, vascular surgery and neurology. The grants were selected for having the greatest potential to quickly and comprehensively determine the significance of CCSVI in the MS disease process. (Read more) The teams are now established and scanning procedures are underway at all but one of the study sites. Researchers have demonstrated a clear willingness to share technical advice and information so that projects can move forward as smoothly as possible. At this six-month milepost they are making significant progress on plans for these two-year studies.
The next update on the work of the seven grantees will be reported in six months.北美對於CCSVI的研究情形update



















關於飲食,你可以更注意